Xin C(1)(2), Liu J(3)(4). Author information:
(1)Stem Cell Clinical Research Center, National Joint Engineering Laboratory,
Regenerative Medicine Center, The First Affiliated Hospital of Dalian Medical
University, No. 193, Lianhe Road, Shahekou District, Dalian City, Liaoning
Province, 116011, People's Republic of China.
(2)Dalian Innovation Institute of Stem Cell and Precision Medicine, No. 57,
Xinda Street, Dalian High-Tech Park, Dalian City, Liaoning Province, 116023,
People's Republic of China.
(3)Stem Cell Clinical Research Center, National Joint Engineering Laboratory,
Regenerative Medicine Center, The First Affiliated Hospital of Dalian Medical
University, No. 193, Lianhe Road, Shahekou District, Dalian City, Liaoning
Province, 116011, People's Republic of China. [Email]
(4)Dalian Innovation Institute of Stem Cell and Precision Medicine, No. 57,
Xinda Street, Dalian High-Tech Park, Dalian City, Liaoning Province, 116023,
People's Republic of China. [Email]
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder and is associated with a range of motor and non-motor clinical symptoms. The underlying molecular pathogenesis of PD involves a variety of pathways and mechanisms, including α-synuclein proteostasis, mitochondrial dysfunction, oxidative stress, autophagy and apoptosis, neuroinflammation, and epigenetic regulation. Long non-coding RNAs (lncRNAs) are involved in the regulation of multiple pathological processes of PD. In this review, we provide an overview of large-scale studies on lncRNA expression profiling in PD patients and models, as well as highlight the impacts of lncRNAs on the pathogenesis of PD, which could provide basic information regarding the putative lncRNA-based biomarkers and therapeutic targets for the early diagnosis and treatment strategies for PD.
OUR JOURNALS
Having over 250 Research scholars worldwide and more than 400 articles online with open access.
